Macrogenics Stock Performance

MGNX Stock  USD 2.18  0.13  6.34%   
The company secures a Beta (Market Risk) of 1.04, which conveys a somewhat significant risk relative to the market. MacroGenics returns are very sensitive to returns on the market. As the market goes up or down, MacroGenics is expected to follow. At this point, MacroGenics has a negative expected return of -0.57%. Please make sure to verify MacroGenics' maximum drawdown, as well as the relationship between the daily balance of power and relative strength index , to decide if MacroGenics performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days MacroGenics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more

Actual Historical Performance (%)

One Day Return
6.34
Five Day Return
(2.68)
Year To Date Return
(33.94)
Ten Year Return
(94.43)
All Time Return
(91.28)
1
Insider Trading
01/02/2025
2
Acquisition by Ferrante Karen Jean of 4500 shares of MacroGenics subject to Rule 16b-3
01/08/2025
3
Macrogenics Stock Hits 52-Week Low at 2.91 Amid Sharp Decline - Investing.com
02/03/2025
4
Disposition of 3475 shares by Jeffrey Peters of MacroGenics at 2.6 subject to Rule 16b-3
02/07/2025
5
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 RD Milestones
02/10/2025
6
WASATCH ADVISORS LP Acquires Additional Shares in Macrogenics Inc
02/12/2025
7
Disposition of 13332 shares by Jeffrey Peters of MacroGenics subject to Rule 16b-3
02/19/2025
8
MacroGenics, Inc. Not Doing Enough For Some Investors As Its Shares Slump 26
02/28/2025
9
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
03/06/2025
10
Acquisition by Beth Smith of 1583 shares of MacroGenics subject to Rule 16b-3
03/07/2025
11
Apyx Medical Reports Q4 Loss, Tops Revenue Estimates
03/13/2025
12
Acquisition by Jackson Scott Thomas of 4500 shares of MacroGenics subject to Rule 16b-3
03/14/2025
13
Acquisition by Ezio Bonvini of 21000 shares of MacroGenics subject to Rule 16b-3
03/18/2025
Begin Period Cash Flow108.9 M
  

MacroGenics Relative Risk vs. Return Landscape

If you would invest  318.00  in MacroGenics on December 20, 2024 and sell it today you would lose (100.00) from holding MacroGenics or give up 31.45% of portfolio value over 90 days. MacroGenics is currently does not generate positive expected returns and assumes 3.817% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than MacroGenics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days MacroGenics is expected to under-perform the market. In addition to that, the company is 4.48 times more volatile than its market benchmark. It trades about -0.15 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly -0.04 per unit of volatility.

MacroGenics Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for MacroGenics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as MacroGenics, and traders can use it to determine the average amount a MacroGenics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.1483

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsMGNX

Estimated Market Risk

 3.82
  actual daily
34
66% of assets are more volatile

Expected Return

 -0.57
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.15
  actual daily
0
Most of other assets perform better
Based on monthly moving average MacroGenics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of MacroGenics by adding MacroGenics to a well-diversified portfolio.

MacroGenics Fundamentals Growth

MacroGenics Stock prices reflect investors' perceptions of the future prospects and financial health of MacroGenics, and MacroGenics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MacroGenics Stock performance.

About MacroGenics Performance

Evaluating MacroGenics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if MacroGenics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if MacroGenics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 48.78  46.34 
Return On Tangible Assets(0.03)(0.04)
Return On Capital Employed(0.80)(0.76)
Return On Assets(0.03)(0.04)
Return On Equity(0.07)(0.07)

Things to note about MacroGenics performance evaluation

Checking the ongoing alerts about MacroGenics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for MacroGenics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
MacroGenics generated a negative expected return over the last 90 days
MacroGenics has high historical volatility and very poor performance
MacroGenics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 58.75 M. Net Loss for the year was (9.06 M) with loss before overhead, payroll, taxes, and interest of (51.3 M).
MacroGenics currently holds about 133.74 M in cash with (78.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18.
Over 94.0% of the company shares are owned by institutional investors
Latest headline from MacroaxisInsider: Acquisition by Ezio Bonvini of 21000 shares of MacroGenics subject to Rule 16b-3
Evaluating MacroGenics' performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate MacroGenics' stock performance include:
  • Analyzing MacroGenics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MacroGenics' stock is overvalued or undervalued compared to its peers.
  • Examining MacroGenics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating MacroGenics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of MacroGenics' management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of MacroGenics' stock. These opinions can provide insight into MacroGenics' potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating MacroGenics' stock performance is not an exact science, and many factors can impact MacroGenics' stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for MacroGenics Stock Analysis

When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.